Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CNOOC
00883
5
SHANGHAI PECHEM
00338
CN Stock MarketDetailed Quotes
Shanghai Shenqi Pharmaceutical Investment Management (600613)
- 5.87
- -0.01-0.17%
Market Closed Apr 29 15:00 CST
3.14BMarket Cap86.32P/E (TTM)
5.93High5.78Low118.12KlotVolume5.85Open5.88Prev Close69.39MTurnover2.46%Turnover Ratio81.53P/E (Static)534.07MShares7.5352wk High1.35P/B2.81BFloat Cap5.3752wk Low6.47Limit Up479.32MShs Float28.95Historical High5.29Limit Down2.55%Range %2.52Historical Low0.15Dividend TTM5.87Avg Price53.26KlotAsk2.56%Div Yield TTM100Lot Size62.20KlotBid
Shanghai Shenqi Pharmaceutical Investment Management (600613) Income Statement
All
YOY
| (Q1)Mar 31, 2026 | (FY)Dec 31, 2025 | (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -11.87%422.94M | -4.71%1.95B | -10.58%1.4B | -13.47%960.85M | -16.47%479.93M | -12.48%2.05B | -8.61%1.56B | -7.91%1.11B | -1.42%574.53M | -2.00%2.34B |
| Operating revenue | -11.87%422.94M | -4.71%1.95B | -10.58%1.4B | -13.47%960.85M | -16.47%479.93M | -12.48%2.05B | -8.61%1.56B | -7.91%1.11B | -1.42%574.53M | -2.00%2.34B |
| Other operating revenue | ---- | 21.45%621.28K | ---- | -85.37%536.46K | ---- | -24.47%511.57K | ---- | 44.59%3.67M | ---- | 212.18%677.34K |
| Total operating cost | -12.72%397.84M | -3.83%1.85B | -11.03%1.32B | -14.19%903.53M | -16.15%455.83M | -12.57%1.92B | -8.97%1.48B | -8.33%1.05B | -1.35%543.62M | -4.69%2.2B |
| Operating cost | -9.16%232.06M | -0.31%1.07B | -7.40%740.08M | -12.57%510.77M | -12.50%255.47M | -8.28%1.08B | -3.13%799.21M | 2.76%584.2M | 8.18%291.96M | 4.19%1.17B |
| Operating tax surcharges | 8.60%10.04M | 1.18%27.23M | 2.30%22.41M | -1.69%14.47M | -7.47%9.24M | -7.42%26.91M | -3.63%21.91M | -10.73%14.72M | -5.25%9.99M | -1.93%29.07M |
| Operating expense | -22.48%124.14M | -10.58%619.13M | -17.41%462.2M | -17.93%317.99M | -24.63%160.13M | -19.92%692.35M | -17.40%559.65M | -21.76%387.48M | -6.80%212.44M | -13.78%864.57M |
| Administration expense | 9.01%23.88M | 7.47%99.57M | 4.89%69.82M | 9.54%44.99M | 17.70%21.91M | 0.13%92.65M | 6.99%66.57M | -0.04%41.08M | -6.28%18.62M | -1.80%92.53M |
| Financial expense | -52.39%675.63K | -36.10%3.11M | -20.91%1.49M | 391.70%1.44M | -13.84%1.42M | -55.41%4.87M | -76.44%1.88M | -95.13%292.63K | -54.74%1.65M | -10.96%10.92M |
| -Interest expense (Financial expense) | -4.44%2.37M | -21.30%10.07M | -20.46%6.97M | -9.69%5.1M | -17.63%2.48M | -13.33%12.8M | -19.58%8.77M | -26.78%5.65M | -40.85%3.02M | -14.98%14.76M |
| -Interest Income (Financial expense) | -57.94%-1.84M | 22.48%-7.44M | 8.32%-6.35M | 36.29%-4.1M | 20.36%-1.16M | -86.00%-9.6M | -91.18%-6.93M | -171.79%-6.43M | -14.37%-1.46M | 19.48%-5.16M |
| Research and development | -8.07%7.04M | -8.05%30.24M | -31.77%21.76M | -44.85%13.85M | -14.55%7.66M | 1.80%32.89M | 1.29%31.9M | 18.14%25.12M | -53.24%8.96M | -29.76%32.3M |
| Credit Impairment Loss | -4.68%-4.09M | -34.25%-21.26M | 46.41%-6.12M | 48.02%-5.97M | -4,427.34%-3.91M | -656.39%-15.84M | -160.61%-11.42M | -159.09%-11.48M | --90.36K | 217.71%2.85M |
| Asset Impairment Loss | -126.91%-1.27M | 29.29%-16.35M | -1,208.09%-12.6M | -506.81%-8.02M | ---558.12K | 68.07%-23.12M | 53.98%-963.5K | 36.89%-1.32M | ---- | -361.85%-72.41M |
| Other net revenue | -24.17%-4M | 14.86%-27.58M | -76.58%-13.84M | -16.88%-11.18M | -484.17%-3.22M | 42.80%-32.4M | -1,798.04%-7.84M | -148.80%-9.57M | -16.12%837.76K | -335.98%-56.64M |
| Fair value change income | 223.82%724.24K | 2,395.61%548.84K | 430.78%1.01M | 235.23%151.13K | 2,939.00%223.66K | -102.66%-23.91K | -153.57%-306.26K | 74.83%45.08K | -112.53%-7.88K | --897.68K |
| Invest income | --230.14K | 137.96%2.99M | ---- | ---- | ---- | 55.34%1.26M | --797.14K | ---- | ---- | -54.10%810.17K |
| -Including: Investment income associates | ---- | 63.91%292.74K | ---- | ---- | ---- | -48.54%178.6K | ---- | ---- | ---- | 433.25%347.03K |
| Asset deal income | ---- | 291.03%227.96K | -81.03%30.3K | ---- | ---- | -144.42%-119.33K | 401.30%159.66K | 303.77%151.92K | 2,940.58%151.92K | 105.19%268.66K |
| Other revenue | -60.15%409.01K | 14.90%6.26M | -1.42%3.84M | -12.70%2.65M | 70.09%1.03M | -50.26%5.45M | -38.53%3.89M | 11.34%3.04M | -35.18%603.36K | 28.60%10.95M |
| Operating profit | 1.07%21.11M | -19.47%73.81M | -10.85%66.26M | -3.69%46.14M | -34.22%20.88M | 10.66%91.67M | -11.50%74.32M | -9.96%47.9M | -3.06%31.75M | 25.80%82.84M |
| Add:Non operating Income | 1,685.72%91.32K | -8.60%234.69K | -81.83%117.18K | -87.79%70.01K | -82.03%5.11K | -72.45%256.77K | -19.01%644.75K | -10.96%573.16K | -79.45%28.45K | -0.84%931.93K |
| Less:Non operating expense | 143.89%1.79M | -26.89%3.18M | -55.78%1.22M | -34.99%752.92K | 88.27%733.93K | 1,096.71%4.35M | 324.41%2.76M | 561.06%1.16M | 3,209.69%389.84K | -89.81%363.16K |
| Total profit | -3.71%19.41M | -19.07%70.87M | -9.77%65.16M | -3.94%45.45M | -35.79%20.15M | 5.00%87.58M | -14.16%72.21M | -11.84%47.32M | -4.53%31.38M | 31.92%83.41M |
| Less:Income tax cost | 66.37%7.38M | 44.36%31.04M | 5.00%14.07M | 31.01%11.04M | -29.16%4.44M | -14.51%21.5M | -28.25%13.4M | -56.03%8.43M | -34.24%6.26M | 68.40%25.15M |
| Net profit | -23.48%12.03M | -39.72%39.84M | -13.13%51.09M | -11.51%34.41M | -37.44%15.72M | 13.42%66.08M | -10.14%58.81M | 12.70%38.89M | 7.59%25.12M | 20.63%58.26M |
| Net profit from continuing operation | -23.48%12.03M | -39.72%39.84M | -13.13%51.09M | -11.51%34.41M | -37.44%15.72M | 13.42%66.08M | -10.14%58.81M | 12.70%38.89M | 7.59%25.12M | 20.63%58.26M |
| Less:Minority Profit | -218.54%-857.16K | 129.96%1.59M | 246.29%789.41K | 52.41%1.61M | -38.64%723.08K | -521.92%-5.31M | -8.20%-539.63K | 564.11%1.05M | 367.98%1.18M | 595.39%1.26M |
| Net profit of parent company owners | -14.07%12.88M | -46.43%38.24M | -15.25%50.3M | -13.29%32.81M | -37.38%14.99M | 25.24%71.39M | -10.00%59.35M | 8.93%37.84M | 0.65%23.94M | 17.41%57M |
| Earning per share | ||||||||||
| Basic earning per share | -33.33%0.02 | -46.15%0.07 | -18.18%0.09 | -14.29%0.06 | -25.00%0.03 | 18.18%0.13 | -8.33%0.11 | 16.67%0.07 | 0.00%0.04 | 22.22%0.11 |
| Diluted earning per share | -33.33%0.02 | -46.15%0.07 | -18.18%0.09 | -14.29%0.06 | -25.00%0.03 | 18.18%0.13 | -8.33%0.11 | 16.67%0.07 | 0.00%0.04 | 22.22%0.11 |
| Other composite income | -41.34%-6.18M | -108.67%-838.78K | -101.67%-223.22K | -157.97%-3.42M | -2,053.58%-4.37M | 100.89%9.67M | 263.89%13.35M | -119.81%-1.32M | -88.74%223.7K | 140.59%4.81M |
| Other composite income of parent company owners | -41.34%-6.18M | -108.67%-838.78K | -101.67%-223.22K | -157.97%-3.42M | -2,053.58%-4.37M | 100.89%9.67M | 263.89%13.35M | -119.81%-1.32M | -88.74%223.7K | 140.59%4.81M |
| Total composite income | -48.44%5.85M | -48.52%39M | -29.51%50.87M | -17.49%31M | -55.23%11.35M | 20.10%75.75M | 4.41%72.17M | -8.81%37.57M | 0.03%25.35M | 73.12%63.07M |
| Total composite income of parent company owners | -36.87%6.71M | -53.85%37.41M | -31.12%50.08M | -19.51%29.39M | -56.04%10.62M | 31.13%81.06M | 4.44%72.71M | -11.86%36.51M | -6.24%24.17M | 68.49%61.81M |
| Total composite income of minority owners | -218.54%-857.16K | 129.96%1.59M | 246.29%789.41K | 52.41%1.61M | -38.64%723.08K | -521.92%-5.31M | -8.20%-539.63K | 564.11%1.05M | 367.98%1.18M | 595.39%1.26M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) | -- | -- | -- | Lixin Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Market Insights
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
New progress emerged in Middle East peace talks on April 29, with Iran expected to submit a revised peace proposal soon. The previous three-
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm